Introduction: Liposomal nanocarriers have been developed aiming to improve targeted drug delivery by enhancing bioavailability and reducing systemic toxicity. Hybrid liposomes, integrating RBC membrane fragments, provide greater stability and biocompatibility. Understanding and optimizing processes like vesicle disruption and membrane fusion are essential steps towards advancing into clinical applications.
Learning Objectives:
Evaluate the stability and membrane fusion properties of conventional and hybrid liposomes.
